Latest total current liabilities for 6744.TWO: $50M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), 6744.TWO shows a total current liabilities of $50M. That compares with $68M in the prior-year period — down 26.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 6744.TWO's total current liabilities is now $50M (was $68M) — a 26.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Feng Chi Biotech is outperforming or lagging.
Tracking 6744.TWO's total current liabilities over time shows whether Feng Chi Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $50M That compares with $68M in the prior-year period — down 26.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total current liabilities page, Stockcircle has Feng Chi Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $50M) with ownership activity and broader fundamentals.
Feng Chi Biotech's total current liabilities is $50M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.